Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$73.78 USD
-0.56 (-0.75%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $73.77 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$73.78 USD
-0.56 (-0.75%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $73.77 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
Zacks News
Biogen (BIIB) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the impact of the coronavirus outbreak on Biogen's (BIIB) performance when it reports first-quarter results.
Gilead (GILD) in Focus: Stock Moves 9.7% Higher
by Zacks Equity Research
Gilead (GILD) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
Gilead Increases Enrollment Target, Pharma Rally Continues
by Ritujay Ghosh
Substantial progress has been made over the past few weeks with pharmaceutical companies speeding up development of coronavirus vaccines.
5 Best Leveraged ETF Areas of Last Week
by Sanghamitra Saha
If investors can identify the trending investing area amid all the coronavirus chaos, they can easily take a leveraged position on that and beat the broader market.
Earnings Scorecard and Top Stock Reports for Alphabet, Gilead & Starbucks
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alphabet (GOOGL), Gilead Sciences (GILD) and Starbucks (SBUX).
Markets Up on COVID-19 Treatment Data
by Mark Vickery
Remsdesivir, a daily infusion treatment from Gilead Sciences (GILD) that has so far shown positive results in a phase-3 study at the University of Chicago Medicine.
Futures Up on Coronavirus Treatment Data
by Zacks Equity Research
Futures Up on Coronavirus Treatment Data
Gilead's (GILD) Coronavirus Drug Shows Promise, Shares Gain
by Zacks Equity Research
Treatment with Gilead's (GILD) experimental antiviral, remdesivir, shows rapid recoveries in fever and respiratory symptoms in COVID-19 patients in a Chicago hospital.
Wall Street to Get Its Mojo Back: Here're the Big Winners
by Tirthankar Chakraborty
Thanks to Trump's plans to reopen U.S. states to Gilead's coronavirus treatment, investors pin hopes on a Wall Street recovery. And with the broader market poised to gain, it seems prudent to pick stocks with solid prospects.
Optimism Back in Wall Street? ETFs Areas to Win the Most
by Sanghamitra Saha
Wall Street is likely to stage a relief rally on hopes of reopening of American businesses, improving virus outlook and chances of treatment coming on stream.
Gilead Brings Likely Coronavirus Cure, Pharma Rallies on R&D
by Ritujay Ghosh
Shares of Gilead Science Inc. (GILD) rally on media reports that severe coronavirus patients were responding positively to the company's experimental treatment, remdesivir.
Gilead Down on Suspension of Coronavirus Study in China
by Zacks Equity Research
Gilead (GILD) declines after a study on investigational antiviral, remdesivir, was suspended in China due to the lack of eligible patients.
The Zacks Analyst Blog Highlights: Pluristem Therapeutics, Mesoblast, Gilead Sciences, Pfizer and Regeneron
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pluristem Therapeutics, Mesoblast, Gilead Sciences, Pfizer and Regeneron
ETFs to Rise as Gilead Drug Shows Promise in Coronavirus Cure
by Sweta Jaiswal, FRM
Gilead Sciences (GILD) has ignited a ray of hope with its recently-released positive data on the role of remdesivir as a COVID-19 treatment.
Pluristem Up on Cell Therapy Treatment of Coronavirus Patient
by Zacks Equity Research
Pluristem (PSTI) gains on the treatment of first patient suffering from COVID-19 complications with its cell therapy.
Will Stem Cell Therapies Aid in Fight Against Coronavirus?
by Ekta Bagri
With the coronavirus outbreak gaining steam worldwide, pharma/biotech companies are evaluating every possible therapy to combat the spread.
Gilead Reports Promising Data on Experimental Coronavirus Drug
by Zacks Equity Research
Gilead (GILD) reports encouraging data on investigational antiviral, remdesivir, in patients hospitalized with COVID-19.
Coronavirus Testing, Vaccines & Treatments: What You Should Know
by Neena Mishra
We discuss latest developments in tests, vaccines and therapies for COVID-19.
Biotech Stock Roundup: AMGN & INCY Focus on Coronavirus Treatments, & More
by Zacks Equity Research
The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.
Biotech Stocks, ETFs to Gain on COVID-19 Vaccine & Drug Progress
by Sweta Jaiswal, FRM
The race to introduce a vaccine and drug for COVID-19 is creating near-term opportunities, making the biotech sector a lucrative space for investments.
Gilead Partners Second Genome, Boosts Coronavirus Drug Production
by Zacks Equity Research
Gilead (GILD) collaborates with Second Genome for inflammatory bowel disease treatments. The company also plans to ramp up production of remdesivir for coronavirus treatment.
Is Pharma the Sector to Bet on in 2020? 2 Big Stocks to Buy
by Kinjel Shah
Here we have highlighted two big pharma stocks that may prove to be good buys. Both these stocks carry a Zacks Rank #1 (Strong Buy) and have seen their share price rise this year.
These Medical ETFs & Stocks Deserve a Salute on Health Day
by Sanghamitra Saha
The World Health Day of 2020 puts these medical companies and the related stocks and ETFs in focus.
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $77.73, moving -0.61% from the previous trading session.
Novo Nordisk's Rybelsus Gets EU Nod for Type II Diabetes
by Zacks Equity Research
Novo Nordisk (NVO) gains the EU approval for Rybelsus to address adult patients with insufficiently-controlled type II diabetes for improving glycemic control as an adjunct to diet and exercise.